LT3452448T - Integruoto signalinio kelio streso moduliatoriai - Google Patents

Integruoto signalinio kelio streso moduliatoriai

Info

Publication number
LT3452448T
LT3452448T LTEPPCT/US2017/031360T LTUS2017031360T LT3452448T LT 3452448 T LT3452448 T LT 3452448T LT US2017031360 T LTUS2017031360 T LT US2017031360T LT 3452448 T LT3452448 T LT 3452448T
Authority
LT
Lithuania
Prior art keywords
modulators
integrated stress
stress pathway
pathway
integrated
Prior art date
Application number
LTEPPCT/US2017/031360T
Other languages
English (en)
Lithuanian (lt)
Inventor
Carmela SIDRAUSKI
Marina Pliushchev
Jennifer Frost
Lawrence Black
Xiangdong Xu
Ramzi Sweis
Lei Shi
Qingwei Zhang
Yunsong Tong
Charles Hutchins
Seungwon CHUNG
Michael Dart
Original Assignee
Calico Life Sciences Llc
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc, Abbvie Inc. filed Critical Calico Life Sciences Llc
Publication of LT3452448T publication Critical patent/LT3452448T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/90—Ring systems containing bridged rings containing more than four rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
LTEPPCT/US2017/031360T 2016-05-05 2017-05-05 Integruoto signalinio kelio streso moduliatoriai LT3452448T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332278P 2016-05-05 2016-05-05
PCT/US2017/031360 WO2017193034A1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway

Publications (1)

Publication Number Publication Date
LT3452448T true LT3452448T (lt) 2024-03-12

Family

ID=58709639

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/031360T LT3452448T (lt) 2016-05-05 2017-05-05 Integruoto signalinio kelio streso moduliatoriai

Country Status (38)

Country Link
US (3) US20190144440A1 (enExample)
EP (2) EP3452448B1 (enExample)
JP (3) JP6997766B2 (enExample)
KR (3) KR102512049B1 (enExample)
CN (2) CN109641844B (enExample)
AR (1) AR110599A1 (enExample)
AU (3) AU2017260367B2 (enExample)
BR (1) BR112018072663A2 (enExample)
CA (1) CA3023162A1 (enExample)
CL (1) CL2018003142A1 (enExample)
CO (1) CO2018012946A2 (enExample)
CR (2) CR20210372A (enExample)
DK (1) DK3452448T3 (enExample)
DO (1) DOP2018000242A (enExample)
EC (1) ECSP18089579A (enExample)
ES (1) ES2973442T3 (enExample)
FI (1) FI3452448T3 (enExample)
HR (1) HRP20240218T1 (enExample)
HU (1) HUE065713T2 (enExample)
IL (3) IL262722B (enExample)
LT (1) LT3452448T (enExample)
MA (1) MA44861B1 (enExample)
MD (1) MD3452448T2 (enExample)
MX (2) MX383652B (enExample)
MY (1) MY200943A (enExample)
PE (2) PE20231935A1 (enExample)
PH (1) PH12018502329B1 (enExample)
PL (1) PL3452448T3 (enExample)
PT (1) PT3452448T (enExample)
RS (1) RS65214B1 (enExample)
RU (2) RU2022106770A (enExample)
SG (1) SG11201809695TA (enExample)
SI (1) SI3452448T1 (enExample)
SM (1) SMT202400098T1 (enExample)
TW (3) TW202506629A (enExample)
UA (1) UA125513C2 (enExample)
UY (1) UY37228A (enExample)
WO (1) WO2017193034A1 (enExample)

Families Citing this family (29)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020522553A (ja) * 2017-06-07 2020-07-30 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ć€ć‚¤ćƒ³ćƒ†ćƒ¬ć‚Æćƒćƒ„ć‚¢ćƒ«ć€ćƒ—ćƒ­ćƒ‘ćƒ†ć‚£ćƒ¼ć€ćƒ‡ć‚£ćƒ™ćƒ­ćƒƒćƒ—ćƒ”ćƒ³ćƒˆć€ćƒŖ惟惆惃惉ļ¼§ļ½Œļ½ļ½˜ļ½ļ½“ļ½ļ½‰ļ½”ļ½ˆļ½‹ļ½Œļ½‰ļ½Žļ½… ļ¼©ļ½Žļ½”ļ½…ļ½Œļ½Œļ½…ļ½ƒļ½”ļ½•ļ½ļ½Œ ļ¼°ļ½’ļ½ļ½ļ½…ļ½’ļ½”ļ½™ ļ¼¤ļ½…ļ½–ļ½…ļ½Œļ½ļ½ļ½ļ½…ļ½Žļ½” ļ¼¬ļ½‰ļ½ļ½‰ļ½”ļ½…ļ½„ ļ¼”ļ½”ļ½†ļ¼”ēµŒč·Æ阻害剤ćØć—ć¦ć®åŒ–åˆē‰©
US20210145771A1 (en) * 2017-07-03 2021-05-20 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
CN111094233B (zh) 2017-08-09 2024-03-15 ꈓēŗ³ē«‹åˆ¶čÆ公åø 化合ē‰©ć€ē»„合ē‰©åŠę–¹ę³•
PT3676297T (pt) 2017-09-01 2023-08-29 Denali Therapeutics Inc Compostos, composiƧƵes e mƩtodos
JP2021501785A (ja) 2017-11-02 2021-01-21 ć‚«ćƒŖć‚³ ćƒ©ć‚¤ćƒ• 悵悤ć‚Øćƒ³ć‚·ćƒ¼ć‚ŗ ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ēµ±åˆēš„ć‚¹ćƒˆćƒ¬ć‚¹ēµŒč·Æ恮čŖæēƀ剤
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vƭa de estrƩs integrada
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vƭa de estrƩs integrada
RU2020122711A (ru) * 2017-12-13 2022-01-17 ŠŸŠ ŠŠšŠ”Š˜Š” Š‘ŠŠ™ŠžŠ¢Š•Šš Š­Š»Š­Š»Š”Šø Š˜Š½Š³ŠøŠ±ŠøтŠ¾Ń€Ń‹ ŠæутŠø ŠøŠ½Ń‚ŠµŠ³Ń€ŠøрŠ¾Š²Š°Š½Š½Š¾Š¹ рŠµŠ°ŠŗцŠøŠø Š½Š° стрŠµŃŃ
US20210130308A1 (en) * 2018-03-23 2021-05-06 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
SG11202011014VA (en) 2018-06-05 2020-12-30 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2021529814A (ja) * 2018-07-09 2021-11-04 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ć€ć‚¤ćƒ³ćƒ†ćƒ¬ć‚Æćƒćƒ„ć‚¢ćƒ«ć€ćƒ—ćƒ­ćƒ‘ćƒ†ć‚£ćƒ¼ć€ćƒ‡ć‚£ćƒ™ćƒ­ćƒƒćƒ—ćƒ”ćƒ³ćƒˆć€ćƒŖ惟惆惃惉ļ¼§ļ½Œļ½ļ½˜ļ½ļ½“ļ½ļ½‰ļ½”ļ½ˆļ½‹ļ½Œļ½‰ļ½Žļ½… ļ¼©ļ½Žļ½”ļ½…ļ½Œļ½Œļ½…ļ½ƒļ½”ļ½•ļ½ļ½Œ ļ¼°ļ½’ļ½ļ½ļ½…ļ½’ļ½”ļ½™ ļ¼¤ļ½…ļ½–ļ½…ļ½Œļ½ļ½ļ½ļ½…ļ½Žļ½” ļ¼¬ļ½‰ļ½ļ½‰ļ½”ļ½…ļ½„ 化学化合ē‰©
TWI832295B (zh) * 2018-10-11 2024-02-11 ē¾Žå•†å˜‰ä¾†å…‹ē”Ÿå‘½ē§‘å­øęœ‰é™č²¬ä»»å…¬åø ę•“åˆę‡‰ęæ€č·Æå¾‘ä¹‹å‰č—„čŖæēƀ劑
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc ComposƩs, compositions et procƩdƩs
CA3129609A1 (en) * 2019-02-13 2020-08-20 Denali Therapeutics Inc. Eukaryotic initiation factor 2b modulators
KR20210134351A (ko) * 2019-02-25 2021-11-09 ķ”„ė½ģ‹œģŠ¤ ė°”ģ“ģ˜¤ķ…Œķ¬ ģ—˜ģ—˜ģ”Ø ķ†µķ•© ģŠ¤ķŠøė ˆģŠ¤ ė°˜ģ‘ ź²½ė”œģ˜ ģ–µģ œģ œ
EA202192900A1 (ru) 2019-04-23 2022-03-18 Š­Š²Š¾Ń‚ŠµŠŗ Š˜Š½Ń‚ŠµŃ€Š½ŠµŃˆŠ½Š» Š“Š¼Š±Ń… ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Ń‹ ŠæутŠø ŠøŠ½Ń‚ŠµŠ³Ń€ŠøрŠ¾Š²Š°Š½Š½Š¾Š¹ рŠµŠ°ŠŗцŠøŠø Š½Š° стрŠµŃŃ
AU2020261234A1 (en) 2019-04-23 2021-11-11 Evotec International Gmbh Modulators of the integrated stress response pathway
AU2020266592A1 (en) * 2019-04-30 2021-12-02 Abbvie Inc. Substituted cyclolakyls as modulators of the integrated stress pathway
PH12021552759A1 (en) * 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
CA3142748A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
PH12022551379A1 (en) * 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
KR20220133252A (ko) 2020-01-28 2022-10-04 ģ—ė³“ķ… ģøķ„°ė‚“ģ…”ė„ ź²Œģ— ė² ķ•˜ ķ†µķ•© ģŠ¤ķŠøė ˆģŠ¤ ė°˜ģ‘ ź²½ė”œģ˜ ģ”°ģ ˆģž
JP2023517944A (ja) 2020-03-11 2023-04-27 ć‚Øćƒ“ć‚©ćƒ†ćƒƒć‚Æćƒ»ć‚¤ćƒ³ć‚æćƒ¼ćƒŠć‚·ćƒ§ćƒŠćƒ«ćƒ»ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆćƒ»ćƒŸćƒƒćƒˆćƒ»ćƒ™ć‚·ćƒ„ćƒ¬ćƒ³ć‚Æćƒ†ćƒ«ćƒ»ćƒćƒ•ćƒ„ćƒ³ć‚° ēµ±åˆēš„ć‚¹ćƒˆćƒ¬ć‚¹åæœē­”ēµŒč·Æ恮čŖæēƀ因子
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
AU2021366303A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
US20230391763A1 (en) 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
JP2023553149A (ja) * 2020-12-10 2023-12-20 ć‚¢ć‚øć‚§ćƒ­ćƒ»ćƒć‚¤ć‚Ŗćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗćƒ»ćƒ›ćƒ¼ćƒ«ćƒ‡ć‚£ćƒ³ć‚°ć‚¹ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ēš®č†šč»¢ē§»ę€§ćŒć‚“ć‚’ę²»ē™‚ć™ć‚‹ę–¹ę³•
KR20250122004A (ko) * 2024-02-05 2025-08-13 ģž¬ė‹Øė²•ģø ėŒ€źµ¬ź²½ė¶ģ²Øė‹Øģ˜ė£Œģ‚°ģ—…ģ§„ķ„ģž¬ė‹Ø ģ‹ ź·œķ•œ eIF2B ģž‘ģš©ģ œ ė° ģ“ė„¼ ķ¬ķ•Øķ•˜ėŠ” ėŒ€ģ‚¬ģ§ˆķ™˜ ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼

Family Cites Families (18)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US162A (en) 1837-04-17 Island
US5212A (en) 1847-07-31 Richard m
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
JP2007517868A (ja) 2004-01-07 2007-07-05 ć‚¢ć‚¹ćƒˆćƒ©ć‚¼ćƒć‚« ć‚¢ć‚Æćƒćƒœćƒ©ć‚° ę²»ē™‚č–¬ļ½‰
GB0400196D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
AU2005267093B2 (en) 2004-07-23 2009-10-01 Nuada Llc Peptidase inhibitors
GB0516314D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Compound
RU2442771C2 (ru) * 2005-08-08 2012-02-20 ŠŃ€Š“Š¶ŠµŠ½Ń‚Š° Š”ŠøсŠŗŠ°Š²ŠµŃ€Šø Š›Ń‚Š“ ŠŸŃ€Š¾ŠøŠ·Š²Š¾Š“Š½Ń‹Šµ Š±ŠøцŠøŠŗŠ»Š¾[2,2,1]Š³ŠµŠæт-7-ŠøŠ»Š°Š¼ŠøŠ½Š° Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
MX2010003249A (es) * 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas sĆ­mil polo.
US8741894B2 (en) * 2010-03-17 2014-06-03 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
CN103025725B (zh) 2010-08-10 2015-09-16 安ę–Æę³°ę„åˆ¶čÆęœ‰é™å…¬åø ꝂēŽÆ化合ē‰©
AR084457A1 (es) * 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
AU2014233520B2 (en) * 2013-03-15 2019-02-21 The Regents Of The University Of California Modulators of the eIF2alpha pathway
WO2015038778A1 (en) * 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2Ī± KINASE ACTIVATORS
EP3489232A3 (en) * 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)

Also Published As

Publication number Publication date
SMT202400098T1 (it) 2024-05-14
US20220363678A1 (en) 2022-11-17
IL262722A (en) 2018-12-31
HUE065713T2 (hu) 2024-06-28
AU2024227527A1 (en) 2024-11-14
DOP2018000242A (es) 2019-04-15
MA44861A (fr) 2019-03-13
MX383652B (es) 2025-03-14
KR20250042188A (ko) 2025-03-26
CR20210372A (es) 2022-06-07
IL262722B (en) 2021-10-31
TWI763668B (zh) 2022-05-11
JP6997766B2 (ja) 2022-01-20
JP7389786B2 (ja) 2023-11-30
MA44861B1 (fr) 2024-02-29
NZ787908A (en) 2025-05-30
PT3452448T (pt) 2024-03-19
CN109641844A (zh) 2019-04-16
KR20230042146A (ko) 2023-03-27
AU2022200946A1 (en) 2022-03-03
EP4356971A2 (en) 2024-04-24
JP2022046578A (ja) 2022-03-23
AU2022200946B2 (en) 2024-07-25
JP2019515043A (ja) 2019-06-06
CN115947681B (zh) 2025-10-14
JP7755632B2 (ja) 2025-10-16
MX2021007146A (es) 2022-11-29
MX2018013495A (es) 2019-07-04
HRP20240218T1 (hr) 2024-04-26
CA3023162A1 (en) 2017-11-09
AU2017260367A1 (en) 2018-11-22
RU2018142740A (ru) 2020-06-05
SG11201809695TA (en) 2018-11-29
PH12018502329B1 (en) 2023-08-11
RS65214B1 (sr) 2024-03-29
KR102781404B1 (ko) 2025-03-18
FI3452448T3 (fi) 2024-03-19
TW202506629A (zh) 2025-02-16
PE20190348A1 (es) 2019-03-07
MY200943A (en) 2024-01-24
UY37228A (es) 2017-11-30
RU2022106770A (ru) 2022-04-05
RU2018142740A3 (enExample) 2020-08-24
CN109641844B (zh) 2022-11-01
DK3452448T3 (da) 2024-02-12
CN115947681A (zh) 2023-04-11
IL286693B1 (en) 2025-11-01
EP3452448A1 (en) 2019-03-13
PL3452448T3 (pl) 2024-07-08
TWI844006B (zh) 2024-06-01
TW201808887A (zh) 2018-03-16
UA125513C2 (uk) 2022-04-13
EP4356971A3 (en) 2024-07-24
CR20180574A (es) 2019-05-15
AU2017260367B2 (en) 2021-12-02
CO2018012946A2 (es) 2019-08-20
KR20190031203A (ko) 2019-03-25
SI3452448T1 (sl) 2024-04-30
ECSP18089579A (es) 2019-02-28
NZ747842A (en) 2025-05-30
ES2973442T3 (es) 2024-06-20
TW202304851A (zh) 2023-02-01
RU2769327C2 (ru) 2022-03-30
MD3452448T2 (ro) 2024-04-30
US20250122188A1 (en) 2025-04-17
IL323840A (en) 2025-12-01
JP2024023324A (ja) 2024-02-21
IL286693A (en) 2021-10-31
BR112018072663A2 (pt) 2019-02-19
CL2018003142A1 (es) 2019-05-24
WO2017193034A1 (en) 2017-11-09
KR102512049B1 (ko) 2023-03-21
EP3452448B1 (en) 2023-12-20
US20190144440A1 (en) 2019-05-16
AR110599A1 (es) 2019-04-17
PH12018502329A1 (en) 2019-03-25
PE20231935A1 (es) 2023-12-05

Similar Documents

Publication Publication Date Title
IL274369A (en) Combined pressure pathway modulators
IL274368A (en) Combined pressure pathway modulators
IL274405A (en) Combined pressure pathway modulators
IL274367A (en) Combined pressure pathway modulators
IL274406A (en) Combined pressure pathway modulators
PT3452454T (pt) Moduladores da via integrada ao stresse
SMT202400098T1 (it) Modulatori della via dello stress integrata
IL300799B2 (en) Prodrugs that modulate integrated stress pathways
IL262303A (en) Modulators of nlrp3
IL259421B (en) ror - gamma modulators
IL271935A (en) NLRP3 modulators
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
GB201716468D0 (en) Modulators
IL266265A (en) Functional chocolate
IL266261A (en) ror-gamma modulators
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORĪ³)
GB2563095B (en) Modulators
GB2549084B (en) Fixing
HK40037522A (en) Modulators of the integrated stress pathway
HK40037177A (en) Modulators of the integrated stress pathway
HK40037528A (en) Modulators of the integrated stress pathway
HK40037523A (en) Modulators of the integrated stress pathway
HK40012048A (en) Modulators of the integrated stress pathway